Regeneron Pharmaceuticals (REGN) Non-Current Debt (2014 - 2026)

Regeneron Pharmaceuticals' Non-Current Debt history runs 9 years deep, the most recent figure standing at $2.0 billion for Q2 2026.

• In Q2 2026, Non-Current Debt changed 0.1% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $2.0 billion (changed 0.1% YoY), while the FY2025 annual figure was $2.0 billion, changed 0.08% from the prior year.
• Non-Current Debt for Q2 2026 stood at $2.0 billion, roughly flat from $2.0 billion in the prior quarter.
• The five-year high for Non-Current Debt was $2.0 billion in Q2 2026, with the low at $2.0 billion in Q1 2022.
• The 5-year median for Non-Current Debt is $2.0 billion (2024), against an average of $2.0 billion.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt advanced 0.1% in 2025, then gained 0.07% in 2026.
• Regeneron Pharmaceuticals' Non-Current Debt stood at $2.0 billion in 2022, then increased by 0.08% to $2.0 billion in 2023, then climbed by 0.08% to $2.0 billion in 2024, then advanced by 0.08% to $2.0 billion in 2025, then increased by 0.05% to $2.0 billion in 2026.
• Business Quant data shows REGN's Non-Current Debt at $2.0 billion in Q2 2026, $2.0 billion in Q1 2026, and $2.0 billion in Q4 2025.